Premium
Cytomegalovirus Disease in High‐Risk Transplant Recipients Despite Ganciclovir or Valganciclovir Prophylaxis
Author(s) -
Akalin Enver,
Sehgal Vinita,
Ames Scott,
Hossain Sabera,
Daly Lisa,
Barbara Murphy,
Bromberg Jonathan S.
Publication year - 2003
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1034/j.1600-6143.2003.00140.x
Subject(s) - valganciclovir , medicine , ganciclovir , cytomegalovirus , cytomegalovirus infection , disease , virology , intensive care medicine , immunology , herpesviridae , human cytomegalovirus , viral disease , virus
The clinical patterns and predictors of cytomegalovirus (CMV) disease in kidney and/or pancreas transplant patients on ganciclovir (1.0 g po t.i.d.) or valganciclovir (450 mg po q.d.) prophylaxis were studied. This is a retrospective analysis of 129 transplant recipients. Median follow up was 12 months (range, 6–18 months). The overall incidence of CMV disease at 1‐year post‐transplant was 14% (4% tissue‐invasive, 10% noninvasive). Seventeen of 18 patients were diagnosed with CMV after completion of 3 months' prophylaxis (median 8 weeks, range, 2–28 weeks). Induction treatment with thymoglobulin, and Donor +/Recipient – CMV status were the strongest predictors for the development of CMV disease. Cytomegalovirus incidence was not different between patients treated with ganciclovir or valganciclovir (15 vs. 17%, respectively).Valganciclovir (450 mg q.d.) is as effective as oral ganciclovir in CMV prophylaxis. High‐risk individuals might require higher doses or longer duration of valganciclovir treatment .